Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System

Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has...

Descripción completa

Detalles Bibliográficos
Autores principales: Barkoff, Courtney M., Mousa, Shaker A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823480/
https://www.ncbi.nlm.nih.gov/pubmed/33374356
http://dx.doi.org/10.3390/biomedicines9010011
_version_ 1783639845575327744
author Barkoff, Courtney M.
Mousa, Shaker A.
author_facet Barkoff, Courtney M.
Mousa, Shaker A.
author_sort Barkoff, Courtney M.
collection PubMed
description Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the potential impact of complement activation in COVID-19 and possible treatments targeting the complement system.
format Online
Article
Text
id pubmed-7823480
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78234802021-01-24 Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System Barkoff, Courtney M. Mousa, Shaker A. Biomedicines Review Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has off-target effects that lead to increases in inflammation, tissue damage, and thrombosis; these are common, life-threatening complications seen in patients with COVID-19. This review explores the potential impact of complement activation in COVID-19 and possible treatments targeting the complement system. MDPI 2020-12-24 /pmc/articles/PMC7823480/ /pubmed/33374356 http://dx.doi.org/10.3390/biomedicines9010011 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Barkoff, Courtney M.
Mousa, Shaker A.
Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
title Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
title_full Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
title_fullStr Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
title_full_unstemmed Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
title_short Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
title_sort pharmacotherapy in covid 19: potential impact of targeting the complement system
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823480/
https://www.ncbi.nlm.nih.gov/pubmed/33374356
http://dx.doi.org/10.3390/biomedicines9010011
work_keys_str_mv AT barkoffcourtneym pharmacotherapyincovid19potentialimpactoftargetingthecomplementsystem
AT mousashakera pharmacotherapyincovid19potentialimpactoftargetingthecomplementsystem

Ejemplares similares